Mobile App for Arthritis
(RAPID-PsA Trial)
Trial Summary
What is the purpose of this trial?
The overall objective of this proposal is to test version 3.0 of the Arthritis smartphone app in a 12-month interrupted time series analysis (ITSA) design which will allow us to observe possible differences in visit frequency between the pre-and post-intervention periods as well as between the concurrent control group and those who receive the app. Our central hypothesis is that introduction of the app will reduce visit numbers per month in the group receiving the app, compared with a concurrent control group.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it requires participants to be using specific medications like guselkumab, infliximab, golimumab, or ustekinumab.
What data supports the effectiveness of the treatment for arthritis using the REMORA smartphone app?
How is the Arthritis smartphone app treatment different from other arthritis treatments?
Research Team
Eligibility Criteria
This trial is for adults over 18 with Psoriatic Arthritis (PsA), diagnosed by a specialist, who've had at least two appointments in the past year. Participants must speak English and own an Android or iPhone smartphone. They should be using specific arthritis medications like guselkumab or infliximab.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
App Integration and Baseline Data Collection
Integration of the app into the EHR and collection of baseline data for PsA patients
Intervention
Participants use the EHR-integrated app to improve visit timeliness and monitor PROs
Follow-up
Participants are monitored for safety and effectiveness after the intervention period
Treatment Details
Interventions
- Arthritis smartphone app (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brigham and Women's Hospital
Lead Sponsor
Dr. William Curry
Brigham and Women's Hospital
Chief Medical Officer
MD from Columbia University College of Physicians and Surgeons
Dr. Scott Schissel
Brigham and Women's Hospital
Chief Executive Officer since 2021
MD from Columbia University College of Physicians and Surgeons
Janssen Scientific Affairs, LLC
Industry Sponsor
Ricardo Attar
Janssen Scientific Affairs, LLC
Chief Executive Officer since 2008
PhD in Molecular Biology, University of Buenos Aires
Dr. Anastasia G. Daifotis
Janssen Scientific Affairs, LLC
Chief Medical Officer since 2023
MD